Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis
Journal of Diabetes & Metabolic Disorders · 23.04.2024 · 23 (1) · 1337-1349
DOI: 10.1007/s40200-024-01431-5 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Diabetes & Metabolic Disorders, online erschienen am 23.04.2024. Verfasst von Varisha Zuhair und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Jinnah Sindh Medical University, Rafiqi H J Shaheed Road, Karachi, Pakistan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Various insulin therapies for Diabetes Mellitus offer different benefits while having potential risks. We aim to compare Insulin Icodec, a novel Insulin analogue with the ease of once-weekly administration, to the once-daily Insulin Glargine U100 regarding glycemic control and safety profile.
Methods
We performed a systematic literature search of electronic databases for peer-reviewed articles from inception until September 1 2023.
Results
A total of 2215 type 2 diabetic patients were included, of which 1209 received Insulin Icodec and1048 recieved Insulin Glargine U100. In terms of glycemic control, Insulin Icodec showed a significantly longer time in the target glucose range (MD: 0.304, CI: 0.069, P = 0.000) and a more significant reduction in HbA1c (MD: -0.154, CI: 0.003, P = 0.005) compared to Insulin Glargine U100. Fasting Plasma Glucose did not differ significantly. Insulin Icodec led to a more significant increase in body weight (MD: 0.161 kg, P = 0.029), while Insulin Glargine required a higher insulin dose (MD: 1.920 IU, P = 0.000). Regarding safety, the two groups had no significant differences in hypoglycemic events or adverse outcomes.
Conclusion
Once-weekly Insulin Icodec demonstrates superior glycemic control with a reduced HbA1c compared to Once-Daily Insulin Glargine U100 while maintaining similar safety profiles. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-024-01431-5.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Jinnah Sindh Medical University, Rafiqi H J Shaheed Road, Karachi, Pakistan.
- Department of Medicine, Bahria University of Health Sciences, Karachi, Pakistan.
ORCID-Profile: Burhanuddin Sohail Rangwala
Zitieren
APA
Zuhair, V., Obaid, M. A., Mustafa, M. S., Shafique, M. A., Rangwala, B. S., Shakil, A., Babar, A., Rangwala, H. S., & Obaid, M. I. (2024). Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis. Journal of Diabetes & Metabolic Disorders, 23(1), 1337-1349. https://doi.org/10.1007/s40200-024-01431-5
Vancouver
Zuhair V, Obaid MA, Mustafa MS, Shafique MA, Rangwala BS, Shakil A, et al. Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis. Journal of Diabetes & Metabolic Disorders. 2024;23(1):1337-1349. doi:10.1007/s40200-024-01431-5
BibTeX
@article{Zuhair2024,
author = {Zuhair, Varisha and Obaid, Muhammad Adil and Mustafa, Muhammad Saqlain and Shafique, Muhammad Ashir and Rangwala, Burhanuddin Sohail and Shakil, Areej and Babar, Areesha and Rangwala, Hussain Sohail and Obaid, Muhammad Ishtiaq},
title = {Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis},
journal = {Journal of Diabetes & Metabolic Disorders},
year = {2024},
volume = {23},
number = {1},
pages = {1337--1349},
doi = {10.1007/s40200-024-01431-5}
}
EUVIMED